HOUSE/SENATE CONFERENCE WILL NOT DERAIL FDA REFORM LEGISLATION, REP. BILIRAKIS PREDICTS; BUDGET TAX BILL COULD BE VEHICLE FOR R&E, ORPHAN EXTENDERS
Executive Summary
Reaching a House/Senate conference agreement on FDA reform should not pose a significant problem, Rep. Bilirakis (R-Fla.) predicted May 6 following a Women in Government Relations meeting in Washington, D.C.